Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
作者信息
Richey Stephen L, Ng Chaan, Lim Zita D, Jonasch Eric, Tannir Nizar M
机构信息
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Clin Oncol. 2011 Mar 10;29(8):e203-5. doi: 10.1200/JCO.2010.31.6091. Epub 2010 Dec 20.
Abstract
摘要
相似文献
1
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.在靶向治疗失败后，吉西他滨联合卡培他滨治疗转移性肾细胞癌实现持久缓解。
J Clin Oncol. 2011 Mar 10;29(8):e203-5. doi: 10.1200/JCO.2010.31.6091. Epub 2010 Dec 20.
2
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
BJU Int. 2011 Mar;107(5):747-748. doi: 10.1111/j.1464-410X.2011.10154.x.
3
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Urologe A. 2004 Sep;43 Suppl 3:S145-6. doi: 10.1007/s00120-004-0608-4.
4
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.吉西他滨联合卡培他滨用于既往接受过免疫治疗和靶向药物治疗的转移性肾细胞癌的II期试验。
J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17.
5
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).多靶点化疗切换方案（索拉非尼、吉西他滨和卡培他滨节拍化疗）治疗转移性肾细胞癌的活性：一项 2 期研究（SOGUG-02-06）。
Lancet Oncol. 2010 Apr;11(4):350-7. doi: 10.1016/S1470-2045(09)70383-3. Epub 2010 Feb 15.
6
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.吉西他滨和卡培他滨治疗晚期肾细胞癌的 II 期研究：西南肿瘤协作组研究 S0312。
Am J Clin Oncol. 2009 Oct;32(5):453-9. doi: 10.1097/COC.0b013e3181925176.
7
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.吉西他滨与卡培他滨固定剂量率用于转移性肾细胞癌的I期试验。
Cancer. 2005 Feb 1;103(3):553-8. doi: 10.1002/cncr.20795.
8
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.索拉非尼联合吉西他滨和顺铂治疗晚期肾细胞癌的 I 期临床试验：纽约癌症联盟试验 NCI 6981。
Am J Clin Oncol. 2011 Oct;34(5):443-8. doi: 10.1097/COC.0b013e3181e9c0d7.
9
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.在靶向治疗背景下的肾癌节拍化疗
Lancet Oncol. 2010 Apr;11(4):307-8. doi: 10.1016/S1470-2045(10)70043-7.
10
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.卡培他滨与吉西他滨联合化疗用于转移性肾癌患者的II期临床试验。
Br J Cancer. 2004 Nov 15;91(10):1763-8. doi: 10.1038/sj.bjc.6602209.
引用本文的文献
1
Management of metastatic renal cell carcinoma - mini review.转移性肾细胞癌的管理——综述
J Kidney Cancer VHL. 2015 May 5;2(2):75-83. doi: 10.15586/jkcvhl.2015.28. eCollection 2015.
2
Chinese guidelines on the management of renal cell carcinoma (2015 edition).《中国肾细胞癌诊疗指南（2015年版）》
Ann Transl Med. 2015 Nov;3(19):279. doi: 10.3978/j.issn.2305-5839.2015.11.21.
3
Adjuvant therapy for renal cell carcinoma: past, present, and future.肾细胞癌的辅助治疗：过去、现在与未来。
Oncologist. 2014 Aug;19(8):851-9. doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26.
4
Gemcitabine induced hemolytic uremic syndrome.吉西他滨诱发溶血尿毒综合征。
Am J Case Rep. 2012;13:89-91. doi: 10.12659/AJCR.882858. Epub 2012 May 25.
5
Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.广泛肉瘤样成分的转移性肾细胞癌的预后因素。
J Cancer Res Clin Oncol. 2013 May;139(5):817-27. doi: 10.1007/s00432-013-1386-4. Epub 2013 Feb 9.
6
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.为肾细胞癌提供预防、预测和个体化的癌症药物：肿瘤异质性的挑战。
EPMA J. 2011 Dec 22;3(1):1. doi: 10.1007/s13167-011-0137-3.
7
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.培美曲塞联合吉西他滨治疗局部晚期和转移性非透明细胞肾细胞癌的 II 期临床试验。
Am J Clin Oncol. 2013 Oct;36(5):450-4. doi: 10.1097/COC.0b013e3182546a91.
8
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.原发性抗血管内皮生长因子 (VEGF) 治疗抵抗转移性肾细胞癌：临床特征、危险因素和后续治疗。
Ann Oncol. 2012 Jun;23(6):1549-55. doi: 10.1093/annonc/mdr533. Epub 2011 Nov 5.
9
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.酪氨酸激酶抑制剂的内在耐药性与转移性肾细胞癌的不良临床结局相关。
BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295.
本文引用的文献
1
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.帕唑帕尼治疗局部晚期或转移性肾细胞癌：一项随机 III 期试验结果。
J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.
2
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.基因和蛋白表达标志物与肾细胞癌联合抗血管生成和表皮生长因子靶向治疗的反应相关。
Ann Oncol. 2010 Aug;21(8):1599-1606. doi: 10.1093/annonc/mdp600. Epub 2010 Jan 20.
3
Detection of chromosomal aberrations in renal tumors: a comparative study of conventional cytogenetics and virtual karyotyping with single-nucleotide polymorphism microarrays.检测肾肿瘤中的染色体异常：常规细胞遗传学与单核苷酸多态性微阵列虚拟核型分析的比较研究。
Arch Pathol Lab Med. 2009 Dec;133(12):1917-22. doi: 10.5858/133.12.1917.
4
5
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.吉西他滨和卡培他滨治疗晚期肾细胞癌的 II 期研究：西南肿瘤协作组研究 S0312。
Am J Clin Oncol. 2009 Oct;32(5):453-9. doi: 10.1097/COC.0b013e3181925176.
6
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.贝伐单抗联合干扰素α与干扰素α单药治疗转移性肾细胞癌患者的比较：CALGB 90206研究
J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
7
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.依维莫司治疗晚期肾细胞癌的疗效：一项双盲、随机、安慰剂对照的III期试验。
Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.
8
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.吉西他滨联合卡培他滨用于既往接受过免疫治疗和靶向药物治疗的转移性肾细胞癌的II期试验。
J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17.
9
Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors.全基因组单核苷酸多态性阵列作为检测肾上皮性肿瘤特征性染色体畸变的潜在诊断工具。
Mod Pathol. 2008 May;21(5):599-608. doi: 10.1038/modpathol.2008.20. Epub 2008 Feb 8.
10
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.贝伐单抗联合干扰素α-2a治疗转移性肾细胞癌：一项随机、双盲III期试验。
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
Zotero 插件